



GUIDELINE RECOMMENDATIONS AND APPROPRIATE TESTING METHODOLOGIES FOR IDENTIFYING *ESR1* MUTATIONS IN ER+, HER2- ADVANCED BREAST CANCER

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommend Comprehensive Genomic Profiling at Diagnosis of mBC¹




Guidelines Recommend Genomic Profiling at Recurrence or Progression on ET in ER+, HER2-mBC²⁻⁵



GUIDELINE RECOMMENDATIONS AND APPROPRIATE TESTING METHODOLOGIES FOR IDENTIFYING *ESR1* MUTATIONS IN ER+, HER2- ADVANCED BREAST CANCER

Identifying Driver Mutations to Inform Treatment Decisions: Liquid vs Tissue Biopsies^{1,2}



Testing for *ESR1* Mutations: PCR-Based vs NGS-Based Assays⁴⁻⁶

